ReviewCells2021
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Subtype-Specific Alterations in Copper Trafficking Associated with KRAS Mutations in Isogenic Colorectal Cancer Cell Lines.Biological trace element research · 2026Article
- Association of Maintenance Therapy Strategies with Survival Following First-Line Bevacizumab-Based Combination Chemotherapy in Metastatic Colorectal Cancer: A Single-Center Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Cancer-associated fibroblasts drive metabolic heterogeneity in colorectal cancer cells: predictions from metabolic modeling.NPJ systems biology and applications · 2026Article
- Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.Journal of gastrointestinal cancer · 2026Article
- Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights.Current cancer drug targets · 2026Review
- Integrative analysis of RAS signaling effectors reveals stage-dependent oncogenic patterns in colon adenocarcinoma.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.Scientific reports · 2025Article
- Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.Scientific reports · 2025Article
- Molecular and Immunohistochemical Biomarkers in Colorectal Carcinoma - A Single Center Study.Balkan journal of medical genetics : BJMG · 2025Article
- The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment.International journal of clinical oncology · 2025Review
- Genomic landscape of pathogenic mutations in Pakistani population with late-stage colorectal cancer.Pakistan journal of medical sciences · 2025Article
- Suppressor protein plasma levels and inflammatory indices in colorectal cancer patients.BMC cancer · 2025Article
- Standardization of a Preclinical Colon Cancer Model in Male and Female BALB/c Mice: Macroscopic and Microscopic Characterization from Pre-Neoplastic to Tumoral Lesions.Biomedicines · 2025Article
- Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Review
- Review
- The Role of TP53, KRAS, CDH1, Demographic and Clinical Variables in Gastric Cancer.Materia socio-medica · 2024Article
- Perfluorooctanesulfonic Acid and Perfluorooctanoic Acid Promote Migration of Three-Dimensional Colorectal Cancer Spheroids.Environmental science & technology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming to collect recent data on KRAS-driven enhanced cell signalling, in vitro and in vivo research models, and CRC development-related processes such as metastasis and cancer stem cell formation. We attempt to cover the diverse nature of the effects of KRAS mutations on age-related CRC development. As the incidence of CRC is rising in young adults, we have reviewed the driving forces of ageing-dependent CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.